The Innovation of the CTC – Where do we go from here?

Gavi perspective

Lauren Franzel
14th TechNet Conference
Bangkok, Thailand

www.gavi.org
# Gavi, the Vaccine Alliance - strategy 2016-2020

**To save children’s lives and protect people’s health**
**by increasing equitable use of vaccines in lower income countries**

## Mission
- Country-led
- Community-owned
- Globally engaged
- Catalytic & sustainable

## Principles
- Integrated
- Innovative
- Collaborative
- Accountable

## Strategic enablers
- A) Country leadership management & coordination
- B) Resource mobilisation
- C) Advocacy
- D) Monitoring & Evaluation

## Goals

### Accelerate equitable uptake and coverage of vaccines
1. Coverage and equity
2. Introduction and scale-up of new vaccines
3. Flexible response to special needs of fragile countries

### Improve sustainability of national immunisation programmes
3. National and sub-national political commitment
4. Allocation and management of national human and financial resources
5. Sustained performance after graduation

### Increase effectiveness and efficiency of immunisation delivery as an integrated part of strengthened health systems
2. Integrated comprehensive immunisation systems
4. Supply chains, health information systems, demand generation and gender sensitive approaches
6. Engagement of civil society, private sector and other partners

### Shape markets for vaccines and other immunisation products
4. Adequate and secure supply
5. Appropriate and sustainable prices
6. Incentivise development of suitable and quality products
CURRENTLY SUPPORTED GAVI VACCINATION PROGRAMMES

**Routine**
- Pentavalent
- Pneumococcal
- Rotavirus
- Human papillomavirus
- Yellow fever
- Measles second dose
- Inactivated polio vaccine

**Campaign**
- Yellow fever
- Meningococcal A
- Measles-rubella
- Japanese encephalitis

**Stockpile** (for outbreak response)
- Yellow fever
- Meningitis
- Cholera
- (Ebola)

**For Board review**
- Malaria

(from left to right): Gavi 2013/Adrian Brooks, Gavi/2012/Saala Lewis, GAVI/Olivier Asselin, Gavi/2012/Adrian Brooks
…WHICH IS UNDERPINNED BY SUPPLY & PROCUREMENT OBJECTIVES

These objectives aim to meet Gavi’s market shaping goal by balancing supply and demand, ensuring security of supply, minimising the cost of vaccines, and fostering development of appropriate and quality vaccines.
Vaccine-specific documents: Short to long term view of how the market should evolve for particular vaccines and identification of mechanisms to influence the supply and price environment and achieve set targets.
Roadmap summary: Oral Cholera

**Ambition**
- Stable supply meets demand
- The market develops a more diverse supply base

**Market Landscape**
- Global demand growing; still unstable
- Anticipate 1-2 new entrants ~2016-18
- Risk = current dependency on 1 supplier

**Target outcomes**
- ≥1 additional supplier between 2016 and 2018
- Improved presentation(s)

**Stakeholder Action Plan**
- Support suppliers to enter market, scale-up, introduce new presentations beyond

Support suppliers to enter market, scale-up, introduce new presentations beyond.
HOWEVER, SOME GAVI VACCINE MARKETS ARE MORE MATURE THAN OTHERS

Manufacturers with pre-qualified vaccines (as of Dec 2014)

<table>
<thead>
<tr>
<th>Vaccine</th>
<th>gsk</th>
<th>Crucell</th>
<th>BE</th>
<th>LG Life Sciences</th>
<th>Panacea Biotec</th>
<th>SANOFI PASTEUR</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pentavalent</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yellow fever</td>
<td></td>
<td>SANOFI PASTEUR</td>
<td></td>
<td>INSTITUT PASTEUR</td>
<td>Bio-Manguinhos</td>
<td></td>
</tr>
<tr>
<td>Rotavirus</td>
<td>gsk</td>
<td>MERCK</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PCV</td>
<td>gsk</td>
<td>Pfizer</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Men A</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MR</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HPV</td>
<td>gsk</td>
<td>MERCK</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IPV</td>
<td>gsk</td>
<td>SANOFI PASTEUR</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>JE</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>SANOFI PASTEUR</td>
<td></td>
</tr>
<tr>
<td>Cholera</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>SANOFI PASTEUR</td>
<td></td>
</tr>
</tbody>
</table>
THANK YOU